Document is current

Article History

Received: 22 February 2021

Accepted: 13 July 2021

First Online: 18 August 2021

Declarations

:

: The RINNOPARI (Recherche et INNOvation en PAthologie Respiratoire Inflammatoire) study was approved by the Ethics Committee of Dijon EST I on 31rd May 2016 (N°2016-A00242-49) and by the French National Agency for Medicines and Health Products (ANSM) on 25th April 2016, and declared on ClinicalTrials.gov (NCT02924818) on 5th October 2016.

: Each patient signed a written informed consent.

: SD reports reimbursements from Novartis and Boehringer Ingelheim, and personal fees from Chiesi outside the submitted work. BR reports reimbursements from Novartis, Mylan, Vertex, Vitalair and Reckitt Benckiser. CLL reports personal fees from Zambon outside the submitted work. MG reports reimbursements from Novartis and Zambon. SC reports reimbursements from Novartis and Vitalaire. FL reports reimbursements from Boehringer Ingelheim and personal fees from Novartis, Boehringer Ingelheim and GlaxoSmithKline outside the submitted work. GD reports personal fees from Nuvaira, AstraZeneca, Boehringer Ingelheim, Chiesi, BTG-PneumRx, and Novartis outside the submitted work.